Company: GEHC
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001932393-25-000053
Chunk: 23

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 1
Chunk 23
---
 2024, respectively.

14

NOTE 7. ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

PROPOSED ACQUISITION.On September 10, 2025, we announced an agreement to acquire icometrix NV, a Belgium based company. The anticipated acquisition aligns with our precision care strategy with a goal of strengthening our portfolio of offerings in neurological care. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including regulatory approval.ACQUISITIONS.Nihon Medi-PhysicsOn March 31, 2025, the Company acquired the remaining 50% interest in Nihon Medi-Physics Co., Ltd. (“NMP”) from joint venture partner Sumitomo Chemical for net cash consideration of $271 million. NMP is a leading pharmaceutical manufacturer in Japan, focused on radiopharmaceuticals, which are used to enable clinical images across neurology, cardiology, and oncology procedures, as well as nonclinical and clinical development of radiotracers and theranostics research. Their product portfolio includes several GE HealthCare radiopharmaceuticals. NMP is included in the Company’s PDx segment.On March 31, 2025, the fair value of the Company’s existing 50% interest in NMP was determined to be $301 million based on the cash consideration exchanged for acquiring the remaining 50% equity interest. The carrying value of our 50% interest was $204 million. The Company recognized a net gain of $97 million resulting from this remeasurement to fair value. This gain included the reclassification of certain amounts related to the Company’s 50% interest out of Accumulated other comprehensive income (loss) – net (“AOCI”) including foreign currency translation gains of $63 million and losses related to a defined benefit pension plan of $8 million. The net gain from this remeasurement was recorded in Other (income) expense – net in the Company’s Condensed Consolidated Statements of Income for the nine months ended September 30, 2025.The following table provides a summary of the purchase price consideration transferred for the acquisition of NMP.Purchase considerationCash consideration, net of cash acquired$271 Fair value of previously held interest in NMP301 Fair value of contingent consideration5 Total allocable purchase price$577 The preliminary fair values of the assets and liabilities assumed in connection with the acquisition of NMP are as follows.Preliminary allocationRe